Articles tagged "Cytomeglovirus"

2021 American Transplant Congress
Efficacy and Safety of a High Dose Ganciclovir Dosing Strategy in Kidney and Pancreas Transplant Recipients
M. Jorgenson¹, J. Descourouez¹, G. Leverson², C. Saddler², J. Smith², D. Mandelbrot², J. Odorico²
¹UW Health, Madison, WI, ²UW School of Medicine and Public Health, Madison, WI
*Purpose: Evaluate efficacy and safety of a strategy utilizing high dose ganciclovir in kidney and pancreas transplant recipients requiring hospital admission for CMV infection.*Methods: Adult…
2021 American Transplant Congress
CD40/40L Pathway is Critical in Controlling CMV Transmission Following Kidney Transplantation in Immunocompromised Mice
X. Lai¹, L. Qiu², J. Wang¹, L. VanOsdol¹, S. Yan³, M. Kandpal⁴, M. Abecassis⁵, Z. Zhang¹
¹Comprehensive Transplant Center, Microsurgery core, Northwestern University, Chicago, IL, ²University of California,, San Francisco, CA, ³Northwestern University, Chicago, IL, ⁴Comprehensive Transplant Center, Northwestern University, Chicago, IL, ⁵University of Arizona, Tucson, AZ
*Purpose: We have previously shown that transplant of kidneys from donor mice latently infected with murine cytomegalovirus (CMV) into naïve recipients treated with clinically relevant…
2021 American Transplant Congress
Impact of Belatacept and Tacrolimus on Cmv Viral Load Control and Relapse in Moderate and High-risk Cmv Serostatus Kidney Transplant Recipients
W. Magua¹, A. C. Johnson¹, G. M. Karadkhele¹, I. R. Badell¹, P. Vasanth¹, M. G. Lyon III², A. K. Mehta², K. A. Easley³, J. Rickert⁴, C. P. Larsen¹
¹Department of Surgery, Emory University, Atlanta, GA, ²Department of Medicine, Emory University, Atlanta, GA, ³Biostatistics and Bioinformatics, Emory University, Atlanta, GA, ⁴RStudio and R Consortium, San Jose, CA
*Purpose: We aim to evaluate the impact of belatacept and tacrolimus on CMV viral load control, remission and relapse in CMV high-risk (serostatus, D+/R-) and…
2021 American Transplant Congress
Single-cell Rna Sequencing of Latent Murine Cytomegalovirus Infected Lung Transplants
L. A. VanOsdol¹, S. Han¹, M. Kandpul², J. J. Wang¹, L. Qiu³, Z. J. Zhang¹
¹Comprehensive Transplant Center, Northwestern University, Chicago, IL, ²Department of Surgery, Northwestern University, Chicago, IL, ³School of Medicine, University of California, San Fransisco, San Fransisco, CA
*Purpose: Analyze the transcriptomics of mouse lung cells with and without latent infection of cytomegalovirus (CMV) before and after transplantation and identify key cell types…
2021 American Transplant Congress
Unquantified Blips Lead to CMV Slips – Post Transplant CMV Monitoring in High Risk Kidney Transplant Recipients
A. T. Payne¹, J. G. Timpone², A. Gilbert², B. Thomas², B. K. Lindner²
¹Georgetown University School of Medicine, Washington, DC, ²Medstar Georgetown University Hospital, Washington, DC
*Purpose: Cytomegalovirus (CMV) is a significant cause of morbidity, mortality, and graft failure after solid organ transplantation, with high risk (D+/R-) patients being the highest…
2021 American Transplant Congress
Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid Organ Transplant Recipients; Single Center Experience
S. Alharbi¹, A. Aljedai², D. Alkortas²
¹Pharmaceutical Care Division, KFSH&RC, riyadh, Saudi Arabia, ²Pharmaceutical Care Division, KFSH&RC, Riyadh, Saudi Arabia
*Purpose: The main objective of the study is to compare the efficacy of the different Valganciclovir dosing strategies in pediatric solid organ transplant recipients with…
2021 American Transplant Congress
An Unusual Viral Tropism in a Solid Organ Transplant Recipient
P. Singh, A. Bentall, C. Langstraat, A. Swanson, P. Deziel, Y. Huang, R. Razonable
Mayo Clinic, Rochester, MN
*Purpose: Cytomegalovirus (CMV) tissue-invasive disease occurs in higher proportion in CMV-mismatched kidney transplant recipients (KTxR) with no pre-existing immunity and those who are markedly immunologically-impaired.…
2021 American Transplant Congress
Outcomes in High Risk CMV Liver Transplants with Elevated MELD Scores
S. Freedman¹, K. Saunders², T. Sparkes¹, B. Masters¹, M. Plazak¹, K. Saharia³, D. Maluf³, B. Ravichandran²
¹University of Maryland Medical Center, Baltimore, MD, ²University of Maryland School of Pharmacy, Baltimore, MD, ³University of Maryland School of Medicine, Baltimore, MD
*Purpose: There is inconclusive evidence on the impact of MELD score on CMV viremia after liver transplantation. Following the implementation of Share 35, liver transplant…
2021 American Transplant Congress
Real-world Treatment Patterns of Antiviral Agents for Cytomegalovirus Among Adult Kidney Transplant Recipients: A USRDS-Medicare Linked Database Study
A. D. Raval¹, M. Ganz², P. Saravanan², Y. Tang¹, C. A. Santos³
¹Merck & Co., Inc., Kenilworth, NJ, ²Evidera, Inc., Waltham, MA, ³Rush University Medical Center, Chicago, IL
*Purpose: Cytomegalovirus (CMV) is a common viral pathogen among kidney transplant recipients (KTRs). Although guidelines recommend the use of prophylaxis or pre-emptive antiviral (AV) therapy…
2021 American Transplant Congress
Impact of Valganciclovir Prophylaxis Dosing in High Risk Cytomegalovirus Kidney and Pancreas Transplant Recipients with Delayed Graft Function
A. Gharabagi¹, J. Geyston¹, A. Agarwal², S. Rao³, A. Doyle³, J. Dann¹
¹Pharmacy, University of Virginia Health System, Charlottesville, VA, ²Transplant Surgery, University of Virginia Health System, Charlottesville, VA, ³Transplant Nephrology, University of Virginia Health System, Charlottesville, VA
*Purpose: We sought to compare outcomes of cytomegalovirus (CMV) prophylaxis in high risk CMV (donor +/recipient -) kidney and pancreas transplant recipients who received different…

« Previous Page
1
…
3
4
5
6
7
…
33
Next Page »